Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2016

View Archived Issues

First preclinical data demonstrate mutant EGFR selectivity of new inhibitor

Novel antibody mixture inhibits tumor growth in MET-amplified models

Bayer Pharma presents preclinical data for the novel anti-TweakR antibody, BAY-356

Pfizer presents highlights of first quarter 2016

Ohr Pharmaceutical develops biodegradable microparticle AMD treatment OHR-3031

Stevia First to become Vitality Biopharma with focus on cannabinoid prodrugs

Cynata Therapeutics and apceth enter license option agreement

Aptinyx completes series A financing

Interim data from Avelas' phase Ib trial of AVB-620 surgical marker

Verona Pharma announces positive phase II results for RPL-554 in patients with COPD

WAVE advances exon 51 DMD candidate and extends research collaboration with University of Oxford

Galapagos initiates phase I trial of its potentiator compound GLPG-2451

CJ CheilJedang reports compounds to treat constipation

Vitae Pharmaceuticals discloses RORgamma inverse agonists

Dermira discloses phase II results for DRM-01

Ferrer to acquire Alexza Pharmaceuticals

Achaogen enters antibody collaboration with Crystal Bioscience

Iron chelator Apo-6856 improves memory in Alzheimer's disease model

Sun Pharma Advanced Research initiates phase I/II study of K-0706

MacroGenics and Pfizer announce first patient dosed with PF-0661008

Janssen plans phase IIb study of AL-335, odalasvir and simeprevir combinations for chronic HCV

FDA grants fast track status to KemPharm's KP-511

New pilot study explores use of ARA-290 for diabetic macular edema

US Phytotherapy conducting preclinical studies of PROACT-Z for Zika infection

Treating Leber's congenital amaurosis type 10 with RNA antisense oligonucleotide QR-110

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...